The most common AEs with semaglutide were gastrointestinal in nature and were mostly mild and comparable in frequency to what has been reported in other populations 16,17
If weight is part of the treatment conversation, discuss the goal, risks, and alternatives with a licensed clinician
How Semaglutide, Vitamin D, and B12 Shots Can Boost Weight-Loss Journey Embarking on a path toward a healthier lifestyle is a significant step that requires the right tools and support
In retatrutide, the GLP-1 arm's insulinotropic effect offsets this, but only if the glucagon component is introduced gradually relative to GLP-1/GIP exposure
He stated, Semaglutide 2.4 mg not only reduces the first event risk but also lowers the cumulative cardiovascular burden making it a foundational therapy for secondary prevention in obesity-related cardiovascular disease Vince Lamanna, President of Novo Nordisk Canada, commented that these results expand the meaning of cardiovascular care by integrating obesity treatment as a proven strategy to prevent future events. He highlighted that Health Canadas decision to approve semaglutide 2.4 mg for patients with established CVD and overweight or obesity was the first global regulatory recognition of obesity therapy as a cardiovascular indication
those with CV risk factors only, and in patients with and without prior MI or stroke